Whole exome sequencing (WES) investigates genetic variations of underlying diseases such as cancers, Mendelian diseases, and complex human disorders. This method targets protein-coding regions responsible for disease-related variants, providing a more cost-effective approach than whole genome sequencing (WGS).
We offer customizable human and mouse WES solutions at the research-use only (RUO) level and clinical whole exome sequencing solutions in our CLIA-certified and CAP-accredited lab.
Whole exome sequencing works by using capture probes (synthesized oligonucleotides) or baits designed to specifically hybridize the exons (coding portions of genes), rather than enriching all the genomic DNA. Library preparation comes next, wherein sequencing adapters are added to the enriched protein-coding DNA fragments and sequenced via high-throughput sequencing, often next generation sequencing (NGS).
An exome sequencing sequence is the protein-coding region of the genome, known as the exome, that is sequenced via next generation sequencing (NGS). The resulting sequencing data is then used to identify genetic variants and influences on disease.
Our research-grade service provides customizable solutions for human and mouse exome sequencing. Flexible service packages are available to meet your budget and deadline requirements.
Our clinical workflows are performed in a CLIA-certified lab by CLIA-trained personnel on CLIA-qualified equipment. Receive the highest level of regulatory compliance with our CLIA-validated clinical exome sequencing assay.
Verify your final targets of interest using GENEWIZ’s confirmatory sequencing service.
Germline variant discovery
Uncovering disease-associated genotypes
Somatic mutation discovery
Tumor/normal sequencing
Exceeding manufacturer's benchmarks
Starting at 1 week for sequencing
Sequencing available at our lab in Leipzig, Germany
Dedicated Ph.D. -level support at every step with real-time project updates through our online system
Flexible data amounts starting at 10M read pairs
Latest platforms - Illumina NovaSeq delivers the highest throughput on the market
Highly scalable - Submit one sample or as many as hundreds
Fragment gDNA, bind probes to exons, and pull down
Add adapters to exon-enriched DNA
Sequence 2x150 bp on Illumina® platform
Identify SNVs, INDELs, gene fusions, and CNVs
Developing immunotherapies for cancer can be difficult due to the variation of immune response from patient to patient. In this webinar, Dr. Litchfield from UCL Cancer Institute presents his team’s exploratory research using a multiomics approach to better understand the diversity of immune response to cancer and highlights their findings of an alternative source of a tumour-specific antigen in checkpoint inhibitor (CPI) response.
For information on our NGS platforms as well as recommended configurations of your projects, please visit the NGS Platforms page. Azenta does not guarantee data output or quality for sequencing-only projects.
GENEWIZ from Azenta Life Sciences
GENEWIZ Germany GmbH, Bahnhofstrasse 86, 04158 Leipzig | +49 (0)341 520 122-41
US
Europe (English)
Chinese
Japanese
